Back to search
FDAFDA · Food and drugs·Recall number D-841-2013

Rifadin, Rifampin capsules, 150 mg, packaged in 30-count bottle, Rx only, Mfd. for Sanofi-Aventis, U.S., LLC, Bridgewater, NJ 08807, NDC 0068-0510-30

Published August 14, 2013 · Recall initiated: March 7, 2013

Summary

FDA records drug Class II recall D-841-2013, published August 14, 2013 and initiated March 7, 2013. Recalling firm: Sanofi US; Status: Terminated; Reported quantity: 2,462 bottles; Lot: Lot # 3097657, Exp 3/15. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug: low fill volume in some of the capsules

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sanofi US
Distributor
Nationwide
Lot
Lot # 3097657, Exp 3/15
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifadin, Rifampin capsules, 150 mg, packaged in 30-count bottle, Rx only, Mfd. for Sanofi-Aventis, U.S., LLC, Bridgewater, NJ 08807, NDC 0068-0510-30 recalled?

Yes. FDA published recall D-841-2013 on August 14, 2013. Reported hazard: Subpotent drug: low fill volume in some of the capsules

What should I do if I have this product?

Voluntary: Firm initiated · Letter